Literature DB >> 26942064

Reviving virus based cancer vaccines by using cytomegalovirus vectors expressing modified tumor antigens.

Zhijuan Qiu1, Jeremy M Grenier1, Kamal M Khanna2.   

Abstract

Cancer vaccines that have utilized various immunization strategies to induce antitumor immunity have largely failed in clinical settings. We have recently developed a cancer vaccine using a cytomegalovirus (CMV) based vector that expressed a modified melanoma antigen that elicited a robust antitumor CD8+ T cell response and tumor rejection.

Entities:  

Keywords:  cancer vaccines; immunotherapy; melanoma; viral vectors

Year:  2015        PMID： 26942064      PMCID： PMC4760325          DOI： 10.1080/2162402X.2015.1056974

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

2.  Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.

Authors:  Marianne J B van Stipdonk; Daniel Badia-Martinez; Marjolein Sluijter; Rienk Offringa; Thorbald van Hall; Adnane Achour
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

3.  Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.

Authors:  Zhijuan Qiu; Huakang Huang; Jeremy M Grenier; Oriana A Perez; Henry M Smilowitz; Barbara Adler; Kamal M Khanna
Journal:  Cancer Immunol Res       Date:  2015-01-29       Impact factor: 11.151

4.  Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus.

Authors:  Scott G Hansen; Colin J Powers; Rebecca Richards; Abigail B Ventura; Julia C Ford; Don Siess; Michael K Axthelm; Jay A Nelson; Michael A Jarvis; Louis J Picker; Klaus Früh
Journal:  Science       Date:  2010-04-02       Impact factor: 47.728

5.  Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells.

Authors:  Christopher M Snyder; Kathy S Cho; Elizabeth L Bonnett; Serani van Dommelen; Geoffrey R Shellam; Ann B Hill
Journal:  Immunity       Date:  2008-10-17       Impact factor: 31.745

6.  Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.

Authors:  Guangwu Xu; Tameka Smith; Finn Grey; Ann B Hill
Journal:  Biochem Biophys Res Commun       Date:  2013-06-27       Impact factor: 3.575

Review 7.  Vaccines and melanoma.

Authors:  Patrick A Ott; Edward F Fritsch; Catherine J Wu; Glenn Dranoff
Journal:  Hematol Oncol Clin North Am       Date:  2014-04-03       Impact factor: 3.722

Review 8.  Neoantigens in cancer immunotherapy.

Authors:  Ton N Schumacher; Robert D Schreiber
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 9.  Cancer vaccines.

Authors:  Lisa H Butterfield
Journal:  BMJ       Date:  2015-04-22

10.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.

Authors:  Fei Duan; Jorge Duitama; Sahar Al Seesi; Cory M Ayres; Steven A Corcelli; Arpita P Pawashe; Tatiana Blanchard; David McMahon; John Sidney; Alessandro Sette; Brian M Baker; Ion I Mandoiu; Pramod K Srivastava
Journal:  J Exp Med       Date:  2014-09-22       Impact factor: 14.307
  10 in total
  4 in total

1.  Murine Cytomegalovirus Infection of Melanoma Lesions Delays Tumor Growth by Recruiting and Repolarizing Monocytic Phagocytes in the Tumor.

Authors:  Nicole A Wilski; Christina Del Casale; Timothy J Purwin; Andrew E Aplin; Christopher M Snyder
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

2.  Optimal CD8+ T-cell memory formation following subcutaneous cytomegalovirus infection requires virus replication but not early dendritic cell responses.

Authors:  Sandra Dimonte; Silvia Gimeno-Brias; Morgan Marsden; Lucy Chapman; Pragati Sabberwal; Mathew Clement; Ian R Humphreys
Journal:  Immunology       Date:  2021-06-13       Impact factor: 7.215

3.  Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors.

Authors:  Jeremy M Grenier; Stephen T Yeung; Zhijuan Qiu; Evan R Jellison; Kamal M Khanna
Journal:  Front Immunol       Date:  2018-01-16       Impact factor: 7.561

4.  Uncovering the Anticancer Potential of Murine Cytomegalovirus against Human Colon Cancer Cells.

Authors:  Layal Massara; Camille Khairallah; Nathalie Yared; Vincent Pitard; Benoit Rousseau; Julien Izotte; Alban Giese; Pierre Dubus; Xavier Gauthereau; Julie Déchanet-Merville; Myriam Capone
Journal:  Mol Ther Oncolytics       Date:  2020-01-29       Impact factor: 7.200
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.